Literature DB >> 414371

Inhibition of aspirin-induced bronchoconstriction by sodium cromoglycate inhalation.

N A Martelli, G Usandivaras.   

Abstract

Five patients with asthma and severe aspirin hypersensitivity were challenged on separate days with increasing doses of aspirin given by mouth, starting with 5 mg, until a reduction in FEV1 greater than 15% was obtained. Sodium cromoglycate in doses of 20-40 mg inhibited the bronchoconstrictive reaction not only when inhaled before the challenge but also after it, at a time when progressive reduction in FEV1 values was taking place. According to these results, it seems reasonable to postulate sequential mast cell degranulation and liberation of mediators of anaphylaxis as the mechanism through which aspirin induces bronchoconstriction in aspirin-sensitive asthmatics. The differences between bronchial provocation tests and oral challenge with aspirin are stressed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 414371      PMCID: PMC470813          DOI: 10.1136/thx.32.6.684

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  23 in total

1.  Bronchial provocation tests in etiologic diagnosis and analysis of asthma.

Authors:  J Pepys; B J Hutchcroft
Journal:  Am Rev Respir Dis       Date:  1975-12

Review 2.  Disodium cromoglycate. Mode of action and its possible relevance to the clinical use of the drug.

Authors:  J S Cox
Journal:  Br J Dis Chest       Date:  1971-10

3.  Nature and modes of action of disodium cromoglycate (Lomudal).

Authors:  J S Cox; R E Altounyan
Journal:  Respiration       Date:  1970       Impact factor: 3.580

4.  Immunologic studies on aspirin. Clinical studies with aspiryl-protein conjugates.

Authors:  A M Yurchak; K Wicher; C E Arbesman
Journal:  J Allergy       Date:  1970-10

5.  Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients.

Authors:  A Szczeklik; R J Gryglewski; G Czerniawska-Mysik
Journal:  Br Med J       Date:  1975-01-11

6.  Duration and specificity of sodium cromolyn on allergen inhalation challenges in asthmatics.

Authors:  B M Kolotkin; C K Lee; R G Townley
Journal:  J Allergy Clin Immunol       Date:  1974-05       Impact factor: 10.793

Review 7.  Immunologic release of chemical mediators from human tissues.

Authors:  M Kaliner; K F Austen
Journal:  Annu Rev Pharmacol       Date:  1975       Impact factor: 13.820

Review 8.  Histamine (first of two parts).

Authors:  M A Beaven
Journal:  N Engl J Med       Date:  1976-01-01       Impact factor: 91.245

9.  Cromoglycate and other antiallergic drugs: a possible mechanism of action.

Authors:  J C Foreman; L G Garland
Journal:  Br Med J       Date:  1976-04-03

10.  Complement components and IgE in patients with asthma and aspirin idiosyncrasy.

Authors:  J C Delaney; A B Kay
Journal:  Thorax       Date:  1976-08       Impact factor: 9.139

View more
  8 in total

1.  Effect of verapamil and sodium cromoglycate on leukotriene D4 induced bronchoconstriction in patients with asthma.

Authors:  J A Roberts; I W Rodger; N C Thomson
Journal:  Thorax       Date:  1986-10       Impact factor: 9.139

2.  Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects.

Authors:  S Nasser; P E Christie; R Pfister; A R Sousa; A Walls; M Schmitz-Schumann; T H Lee
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

Review 3.  Prostaglandins and the lung.

Authors:  S P Hanley
Journal:  Lung       Date:  1986       Impact factor: 2.584

4.  Inhibition of idiosyncratic reactions to aspirin in asthmatic patients by clemastine.

Authors:  A Szczeklik; M Serwonska
Journal:  Thorax       Date:  1979-10       Impact factor: 9.139

Review 5.  Natural history and clinical features of aspirin-exacerbated respiratory disease.

Authors:  John M Fahrenholz
Journal:  Clin Rev Allergy Immunol       Date:  2003-04       Impact factor: 8.667

6.  Aspirin-like drugs interfere with arachidonate metabolism by inhibition of the 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid peroxidase activity of the lipoxygenase pathway.

Authors:  M I Siegel; R T McConnell; P Cuatrecasas
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

Review 7.  Analgesics, allergy and asthma.

Authors:  A Szczeklik
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Arachidonate metabolism via lipoxygenase and 12L-hydroperoxy-5,8,10,14-icosatetraenoic acid peroxidase sensitive to anti-inflammatory drugs.

Authors:  M I Siegel; R T McConnell; N A Porter; P Cuatrecasas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.